A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

Last updated: March 14, 2025
Sponsor: AbbVie
Overall Status: Completed

Phase

1

Condition

Generalized Anxiety Disorder (Gad)

Anxiety Disorders

Mood Disorders

Treatment

Placebo for ABBV-932

ABBV-932

Clinical Study ID

NCT06024239
M23-893
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder (GAD), and participants with bipolar disorder (BPD).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • For healthy volunteer cohort:

-- Body mass index (BMI) is >= 18.0 to <= 32.0 kg/m2 after rounding to the tenthsdecimal.

  • For participants with generalized anxiety disorder (GAD) or bipolar disorder (BPD)

  • Participants with GAD or BPD (as confirmed by MINI) meet participantpsychiatric history criteria described in the protocol.

Exclusion

Exclusion Criteria:

  • History of any clinically significant illness/infection/major febrile illness,hospitalization, or any surgical procedure within 30 days prior to the first dose ofstudy drug.

Study Design

Total Participants: 72
Treatment Group(s): 2
Primary Treatment: Placebo for ABBV-932
Phase: 1
Study Start date:
August 31, 2023
Estimated Completion Date:
March 04, 2025

Connect with a study center

  • Cenexel CNS /ID# 260270

    Los Alamitos, California 90720-3118
    United States

    Active - Recruiting

  • Collaborative Neuroscience Research CNS /ID# 260270

    Los Alamitos, California 90720
    United States

    Site Not Available

  • Acpru /Id# 255945

    Grayslake, Illinois 60030
    United States

    Site Not Available

  • CenExel HRI /ID# 260271

    Marlton, New Jersey 08053-3424
    United States

    Active - Recruiting

  • Hassman Research Institute Marlton Site /ID# 260271

    Marlton, New Jersey 08053
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.